Organisation paid for research Program year 2025 Source: CMS Open Payments

Celerion

Neither a doctor nor a teaching hospital

Research payments

$18,601,003

149 payments

Through program year 2025, Celerion is reported as receiving $18,601,003 in research payments, across 149 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$1,721,216	4
2024	Research	$2,743,910	7
2023	Research	$2,455,173	21
2022	Research	$616,264	2
2021	Research	$1,374,622	9
2020	Research	$7,081,303	50
2019	Research	$2,608,516	56

Breakdown

Who paid Research payments · program years 2019–2025

Novartis Pharmaceuticals Corporation $4,437,340 9 payments
Vertex Pharmaceuticals Incorporated $4,265,447 6 payments
Merck Sharp & Dohme Corporation $3,584,195 39 payments
Indivior Inc. $2,509,163 23 payments
Novo Nordisk AS $2,235,322 57 payments
Sage Therapeutics, Inc. $513,726 2 payments
Horizon Therapeutics plc $372,876 1 payment
Janssen Research & Development, LLC $352,416 4 payments
BioCryst Pharmaceuticals, Inc. $330,518 8 payments

Studies the money was for Research payments · program years 2019–2025

A Randomized, Open-Label, Single-Dose, Parallel-Group Study in Healthy Subjects to Assess the PK Comparability of Canakinumab With Either One Injection (200 MG) of Pre-Filled Syringe in Needle Safety Device Or Auto-Injector Compared to Two Injections (150 $1,834,124 2 payments
CLNP023A2109 high dose MAD in HVs $1,582,192 1 payment
A Phase 1, Open-label, Non-randomized, Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion of 14C-VX-864 Following Single Oral Administration in Healthy Subjects $1,503,685 1 payment
An Open Label, Fixed-sequence Study to Evaluate the Potential CYP3A4 Induction Effect of INDV-2000 Using Oral Midazolam as a Probe in Healthy Adults Participants $1,301,108 10 payments
Nn9775-4398 $1,284,766 29 payments
An Open-Label, Phase 1 Study to Characterize the Effects of Belzutifan on the Pharmacokinetics of a MATE1,2K Substrate, Metformin, in Healthy Adult Participants $1,059,481 1 payment
An Open-label Phase 1 Study to Examine the Effect of VX-864 on the Pharmacokinetics of Pitavastatin, Midazolam, and Atorvastatin in Healthy Subjects $993,258 1 payment
Nn9747-4261 $950,556 28 payments
Indv-2000-103 $873,757 7 payments
A Study to Evaluate the Definitive Bioequivalence of Tedizolid Phosphate Single-Unit-Dose Sachet Powder for Oral Suspension Compared to Tedizolid Phosphate Powder for Oral Suspension Bottle Used in Pediatric Clinical Studies. $805,390 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.